Condition | Emax relaxation | pD2 | n |
Sham without LV series | 10%±9% | 6.05±1.16 | 5 |
Sham with LV series | 54%±17%* | 5.38±0.91 | 5 |
SAH day 3 with LV series | 64%±22%* | 4.77±0.72 | 5 |
After precontraction with prostaglandin F2alpha, LV induced a dose-dependent vasorelaxation. Emax was significantly enhanced in the SAH day 3 and sham group, compared with the solvent control series. Values are expressed as mean±SD.
*P<0.05 vs solvent control.
LV, levosimendan; SAH, subarachnoid hemorrhage.